Abstract

Regions of protein-tyrosine phosphatase (PTP) 1B that are distant from the active site yet affect inhibitor binding were identified by a novel library screen. This screen was based on the observation that expression of v-Src in yeast leads to lethality, which can be rescued by the coexpression of PTP1B. However, this rescue is lost when yeast are grown in the presence of PTP1B inhibitors. To identify regions of PTP1B (amino acids 1-400, catalytic domain plus 80-amino acid C-terminal tail) that can affect the binding of the difluoromethyl phosphonate (DFMP) inhibitor 7-bromo-6-difluoromethylphosphonate 3-naphthalenenitrile, a library coexpressing PTP1B mutants and v-Src was generated, and the ability of yeast to grow in the presence of the inhibitor was evaluated. PTP1B inhibitor-resistant mutations were found to concentrate on helix alpha7 and its surrounding region, but not in the active site. No resistant amino acid substitutions were found to occur in the C-terminal tail, suggesting that this region has little effect on active-site inhibitor binding. An in-depth characterization of a resistant substitution localizing to region alpha7 (S295F) revealed that this change minimally affected enzyme catalytic activity, but significantly reduced the potency of a panel of structurally diverse DFMP PTP1B inhibitors. This loss of inhibitor potency was found to be due to the difluoro moiety of these inhibitors because only the difluoro inhibitors were shifted. For example, the inhibitor potency of a monofluorinated or non-fluorinated analog of one of these DFMP inhibitors was only minimally affected. Using this type of library screen, which can scan the nearly full-length PTP1B sequence (catalytic domain and C-terminal tail) for effects on inhibitor binding, we have been able to identify novel regions of PTP1B that specifically affect the binding of DFMP inhibitors.

Highlights

  • Inhibitor, providing an understanding of the mechanism of inhibition

  • Use of Yeast to Identify Amino Acid Determinants of PTP1B Inhibitor Binding—Recently, we reported on a yeast assay to screen for PTP1B inhibitors [12]

  • This rescue is reversed when yeast cells coexpressing v-Src and PTP1B are grown in the presence of PTP1B inhibitors

Read more

Summary

Introduction

Inhibitor, providing an understanding of the mechanism of inhibition This is normally accompanied by site-directed mutagenesis of the interacting residues to validate their role in inhibitor binding and to determine the degree to which this interaction contributes to inhibitor potency. Protein-tyrosine phosphatase (PTP)3 1B (EC 3.1.3.48), a potential drug target for the treatment of diabetes and obesity [1, 2], has had a number of published inhibitor-enzyme complexes, and the determinants required for the binding of various inhibitors have been identified. Because these inhibitors all target the active site, the determinants identified are located in the active-site region. The assay is based on the observation that expression of v-Src in

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call